Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 125B 84.03M 73.05M 67.99M 62.43M 118M 8.02B 120M 801M 315M 3.99B 316M 309M 13.39B P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 356B 239M 208M 193M 178M 335M 22.83B 341M 2.28B 895M 11.37B 898M 878M 38.11B EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
11/05 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
08/05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/03 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
06/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
08/08/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
10/05/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/05/25 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/03/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/11/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/08/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
07/05/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/03/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
10/11/23 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
1 day+0.32%
1 week+0.65%
1 month-1.27%
3 months-5.20%
6 months-22.11%
Current year-21.52%
1 week 1,520
Extreme 1520
1,595
1 month 1,495
Extreme 1495
1,610
Current year 1,420
Extreme 1420
2,130
1 year 945
Extreme 945
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%+0.65%+3.68%+190.26% 84.03M
-0.53%-3.95%+55.23%+152.74% 1,024B
+0.21%-2.68%+55.61%+53.02% 618B
-2.51%-3.25%+32.76%+67.76% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.14%-0.24%+34.41%+39.01% 297B
-0.69%-0.30%+11.55%+12.93% 264B
-7.37%-4.40%-2.54%-43.87% 209B
-0.64%+2.43%+30.52%+64.49% 208B
-0.82%+0.70%+15.96%+71.01% 162B
Average -1.21%-0.95%+27.47%+63.80% 357.38B
Weighted average by Cap. -0.99%-1.93%+39.24%+72.96%

Financials

2024 2025
Net sales 91.79B 61.63M 53.57M 49.86M 45.78M 86.46M 5.88B 87.79M 588M 231M 2.93B 231M 226M 9.82B 127B 85.08M 73.96M 68.84M 63.2M 119M 8.12B 121M 811M 318M 4.04B 320M 313M 13.56B
Net income 23.85B 16.01M 13.92M 12.95M 11.89M 22.46M 1.53B 22.81M 153M 59.92M 761M 60.12M 58.8M 2.55B 3.09B 2.07M 1.8M 1.68M 1.54M 2.91M 198M 2.95M 19.77M 7.76M 98.52M 7.79M 7.61M 330M
Net Debt 134B 89.73M 78M 72.6M 66.66M 126M 8.57B 128M 856M 336M 4.26B 337M 330M 14.3B 231B 155M 135M 126M 115M 218M 14.81B 221M 1.48B 581M 7.37B 583M 570M 24.72B
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
31/07/26 ARS 1,550.00 +0.32% 26,344
30/07/26 ARS 1,545.00 +0.32% 27,313
29/07/26 ARS 1,540.00 -.--% 31,156
28/07/26 ARS 1,540.00 +0.65% 400
27/07/26 ARS 1,530.00 -0.65% 34,559
  1. Stock Market
  2. Stocks
  3. RICH Stock